Induction of Protective Immunity against Toxoplasmosis in BALB/c Mice Vaccinated with Toxoplasma gondii Rhoptry-1 by Parthasarathy Sonaimuthu et al.
fmicb-07-00808 May 25, 2016 Time: 16:29 # 1
ORIGINAL RESEARCH











Instituto Nacional de Pediatria, Mexico
Alexandre Morrot,






This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 21 December 2015
Accepted: 12 May 2016
Published: 27 May 2016
Citation:
Sonaimuthu P, Ching XT, Fong MY,
Kalyanasundaram R and Lau YL
(2016) Induction of Protective
Immunity against Toxoplasmosis




Induction of Protective Immunity
against Toxoplasmosis in BALB/c
Mice Vaccinated with Toxoplasma
gondii Rhoptry-1
Parthasarathy Sonaimuthu1, Xiao T. Ching1, Mun Y. Fong1,
Ramaswamy Kalyanasundaram2 and Yee L. Lau1*
1 Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2 Department of Biomedical
Sciences, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
Toxoplasma gondii is the causative agent for toxoplasmosis. The rhoptry protein 1
(ROP1) is secreted by rhoptry, an apical secretory organelle of the parasite. ROP1
plays an important role in host cell invasion. In this study, the efficacy of ROP1 as
a vaccine candidate against toxoplasmosis was evaluated through intramuscular or
subcutaneous injection of BALB/c mice followed by immunological characterization
(humoral- and cellular-mediated) and lethal challenge against virulent T. gondii RH
strain in BALB/c mice. Briefly, a recombinant DNA plasmid (pVAX1-GFP-ROP1) was
expressed in CHO cells while expression of recombinant ROP1 protein (rROP1) was
carried out in Escherichia coli expression system. Immunization study involved injection
of the recombinant pVAX1-ROP1 and purified rROP1 into different group of mice.
Empty vector and PBS served as two different types of negative controls. Results
obtained demonstrated that ROP1 is an immunogenic antigen that induced humoral
immune response whereby detection of a protein band with expected size of 43 kDa
was observed against vaccinated mice sera through western blot analysis. ROP1
antigen was shown to elicit cellular-mediated immunity as well whereby stimulated
splenocytes with total lysate antigen (TLA) and rROP1 from pVAX1-ROP1 and rROP1-
immunized mice, respectively, readily proliferated and secreted large amount of IFN-γ
(712 ± 28.1 pg/ml and 1457 ± 31.19 pg/ml, respectively) and relatively low IL-4 level
(94 ± 14.5 pg/ml and 186 ± 14.17 pg/ml, respectively). These phenomena suggested
that Th1-favored immunity was being induced. Vaccination with ROP1 antigen was able
to provide partial protection in the vaccinated mice against lethal challenge with virulent
RH strain of tachyzoites. These findings proposed that the ROP1 antigen is a potential
candidate for the development of vaccine against toxoplasmosis.
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INTRODUCTION
Toxoplasma gondii is an obligate intracellular parasite that infects various cell types to cause
an infection known as toxoplasmosis (Kim and Weiss, 2004). Although the infection is usually
asymptomatic, it may sometimes lead to severe complications, including brain lesions, encephalitis,
and neurological diseases. The risk is highest in immunocompromised patients. Infants affected
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by congenital toxoplasmosis can develop hydrocephalus,
convulsions, microcephaly, motor retardation, anemia, and
intracerebral calcification. T. gondii infections in livestock can
result in abortion or stillbirth, causing major economic losses
worldwide (Buxton, 1998).
Current therapies against T. gondii are toxic and expensive.
They are designed to control newly acquired infections, but
not for treating chronic toxoplasmosis. Thus, vaccination is
considered as an effective approach for preventing T. gondii
infection. However, the only available vaccine for toxoplasmosis
to date is derived from live attenuated T. gondii (non-cyst-
forming S48 strain). It is only used for sheep in Europe and
New Zealand (Buxton et al., 1991; Jongert et al., 2009). It
is not suitable for human use because of the risks associated
with reversion of the parasite to its pathogenic form (Weeks-
Levy et al., 1991; Bourguin et al., 1993). To date, various
T. gondii antigens, such as microneme proteins (Lourenco
et al., 2006; Peng et al., 2009; Yan et al., 2012), dense
granule proteins (Golkar et al., 2007; Jongert et al., 2008;
Hiszczynska-Sawicka et al., 2011b; Sun et al., 2011), rhoptry
antigens (Chen et al., 2003; Yuan et al., 2011a; Dziadek
et al., 2012), matrix proteins (Di Cristina et al., 2004), and
surface antigens (Khan et al., 1991; Mevelec et al., 2005;
Lau et al., 2011) have been assessed as potential vaccination
candidates.
DNA vaccines are considered as an alternative approach
to live, attenuated vaccines because they can elicit long-lived
immune responses in animal (Robinson, 1999; Gurunathan
et al., 2000). Moreover, these vaccines have been seen to
be safe and effective in controlling T. gondii infection (Liu
et al., 2012). Cellular immune responses generated through
immunization are particularly important for combating T. gondii,
and intramuscular DNA vaccines are known to induce both
cellular and humoral immunity (Denkers and Gazzinelli, 1998).
Subunit vaccines are known to trigger predominantly humoral
immune responses and this is characterized by isotopic diversity
of the antibodies with different effector functions; in particular
complement activation and binding to phagocytic and killer
cells through Fc receptors (Janeway et al., 2001). Efficient
humoral responses require cooperation between B and specific
T helper (Th) cells. The cells are divided into two distinct
subpopulations, based on the cytokines they secrete and their
effector functions. For example, Th1 cells produce mainly IL-2,
IFN-γ, and TNF-β, and they stimulate a cellular delayed type
hypersensitivity response. In contrast, Th2 cells produce IL-4,
IL-5, IL-10, and IL-13 cytokines (Romagnani, 1994; Abbas et al.,
1996).
Host cell invasion by T. gondii is mediated by proteins
which are present in the apical complex secretory organelles
(micronemes, dense granules, and rhoptries; Saeij et al.,
2006). The rhoptries are involved in the formation of the
parasitophorous vacuoles in which the parasites proliferate, thus
avoiding host immune defenses (Carey et al., 2004; Dlugonska,
2008). Numerous investigations have been carried out on rhoptry
protein 1 (ROP1), ROP2, ROP16, and ROP18 as potential vaccine
candidates (Chen et al., 2001; Leyva et al., 2001; Yuan et al.,
2011a,b).
DNA vaccine of ROP1 has been shown to elicit immunity in
animal models (Chen et al., 2001; Guo et al., 2001). ROP1 in
combination with SAG1 has been shown to induce protective
immunity in mice (Chen et al., 2003). DNA vaccine combining
ROP1 gene with ovine CD154 triggers a mixed Th1/Th2 immune
response in sheep, whereas ROP1 alone induces only Th1-specific
immunity (Hiszczynska-Sawicka et al., 2011a). A DNA vaccine
cocktail containing recombinant ROP1 (rROP1) and GRA7 was
also tested with and without adjuvant pIL-12 in mice. The
multivalent vaccine ROP1-GRA7 with pIL12 showed stronger
Th1 immune response and protective efficiency than the ROP1
alone (Quan et al., 2012). Studies thus far only report the type
of immune responses triggered by ROP1-based DNA vaccine,
and no challenge experiments against acute infection have been
conducted. The present study is the first to demonstrate the
immuno-protectivity of ROP1-based DNA vaccine and rROP1
against acute Toxoplasma infection in BALB/c mice.
MATERIALS AND METHODS
Mice
Female BALB/c mice (5–6 weeks old) were purchased from
University of Malaya Animal Experimental Center and housed
in a pathogen-free environment. Experiments involving mice
model were performed in compliance with the animal ethics
approved by Institutional Animal Care and Use Committee
(IACUC) of University of Malaya, Faculty of Medicine (2014-06-
03/PARA/R/CXT).
Parasites
Highly virulentT. gondii tachyzoites (RH strain) were maintained
via successive intraperitoneal passage in mice. Parasites were
collected from the intraperitoneal fluid, washed with phosphate
buffered saline (PBS), and filtered through 3 µm polycarbonate
filters. The filtrate obtained was centrifuged at 1,500 rpm for
10 min and re-suspended in PBS prior to use.
Preparation of Total Lysate Antigen (TLA)
Total lysate antigen (TLA) of the parasite was extracted from the
suspension of tachyzoites through repeated freeze-thaw methods
(5–10 cycles of freezing in liquid nitrogen and thawing in 37◦C
water bath with 2–3 min each step) followed by centrifugation of
the lysate at 3000 × g for 15 min at 4◦C. Supernatant containing
TLA was collected and stored at−80◦C until used.
Construction of Recombinant Plasmids
Eukaryotic Expression Plasmids
The 1,191 bp ROP1 coding sequence (GenBank ID: M71274) was
amplified by PCR from genomic DNA of T. gondii tachyzoites
using gene-specific forward (5′-CGCGGATCCACGATGGAG
CAAAGGCTGCCAA-3′) and reverse (5′-CGGAATTCTTATTG
CGATCCATCATCCTGC-3′) primers, introducing Bam HI and
Eco R1 restriction sites (as underlined). The PCR product was
cloned into the respective restriction sites of pVAX1 (Invitrogen,
USA) and pVAX1-GFP vectors. The constructs were verified by
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sequencing in both directions to ensure fidelity (GenScript Inc.,
Piscataway, NJ, USA).
Prokaryotic Expression Plasmids
The 1,191 bp ROP1 coding sequence (GenBank ID:
M71274) was amplified by PCR from genomic DNA
of the T. gondii tachyzoites with gene-specific forward
(5′-GAATTCCTACTTGTTCTCTCTGTG-3′) and reverse (5′-
GGATCCTTGCGATCCATCATCCTG-3′) primers, introducing
Eco R1 and Bam HI restriction sites (as underlined). The PCR
product was cloned into the respective restriction sites of
pCold I vector (Invitrogen, USA). The constructs were verified
by sequencing in both directions to ensure fidelity (Bioneer
Corporation, South Korea). Both the rROP1 construct and
non-recombinant pCold I plasmid were transformed into the
prokaryotic expression host, E. coli BL21 (DE3) prior to protein
expression.
In Vitro Expression of pVAX1-GFP-ROP1
Chinese Hamster Ovary (CHO) cells were transfected with
pVAX1-GFP-ROP1 plasmid (3 µg/µl) using TurboFect
(Fermentas Inc., Glen Burnie, MA, USA) according to the
manufacturer’s instructions. Expression of green fluorescent
protein (GFP)-tagged ROP1 was observed under inverted
florescence microscope (Olympus, Hicksville, NY) at 24, 48,
and 72 h post transfection. The expression was also detected
by western blot assay using monoclonal anti-GFP antibody
(Invitrogen, Grand Island, NY, USA) and toxoplasmosis-
positive patient serum (Diagnostic Laboratory [Para: SEAD],
Department of Parasitology, University of Malaya). CHO cells
transfected with pVAX1-GFP vector was included as positive
control.
Recombinant Protein Expression of
pCold I-ROP1 (rROP1) in BL21 (DE3)
A single colony of pCold I-ROP1 was inoculated into 5 ml
of LB broth supplemented with ampicillin (100 µg/ml) and
chloramphenicol (34 µg/ml) before growing overnight at 37◦C,
with 250 rpm shaking. One percent of the overnight culture
was inoculated into 10 ml of LB medium and grown at 37◦C,
250 rpm until the OD600 reached 0.5–0.6. The culture was
then incubated at 15◦C for 30 min followed by the addition
of 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG). The cells
were again allowed to grow overnight with constant shaking at
15◦C, 250 rpm. The culture was harvested by centrifugation at
10,000 rpm for 10 min the next day. Cell pellet obtained was
subjected to purification.
One-Step Protein Purification of rROP1
Protein expressed was purified under native condition using
ProBondTM Purification system (Invitrogen, USA) according to
the manufacturer’s instructions. The cell pellet obtained was re-
suspended in the binding buffer before subjected to sonication for
60 s at 10 s interval. The sonicated cell lysate was then centrifuged
at 10,000 × g for 30 min, 4◦C. Supernatant was collected and
loaded into the pre-equilibrated purification column containing
2 ml nickel-nitrilotriacetic acid (Ni-NTA) resin (Invitrogen,
USA). Supernatant containing rROP1 was allowed to bind to
the resin at room temperature for 3 h. After binding, the
resin with bound protein was washed with buffers containing
imidazole with increasing concentrations (5, 10, and 15 mM,
respectively) in order to remove contaminant proteins that
bound unspecifically to the resin. Target protein was eventually
eluted with elution buffer containing 200 mM imidazole. Eluted
rROP1 was subjected to dialysis overnight with PBS to remove
unwanted salt from the protein. Purity and identity of the
purified protein was analyzed through SDS-PAGE and western
blot analysis.
SDS-PAGE and Western Blot Analysis
Purified rROP1 was resolved by SDS-PAGE on 12%
polyacrylamide gel and transferred onto methanol-activated
polyvinylidene difluoride (PVDF; Bio-Rad, USA) membrane.
The membrane were incubated with blocking solution (5%
non-fat skim milk in Tris Buffered Saline, TBS) for 2 h at room
temperature with constant shaking and were subsequently
probed with monoclonal anti-His (Invitrogen, USA; 1:5000)
for 2 h. The membrane was washed and then incubated for
1 h with biotinylated goat anti-mouse IgG (KPL, USA; 1:2500)
secondary antibody. Lastly, the membrane was washed and
incubated with streptavidin-alkaline phosphatase (KPL, USA;




Six groups of BALB/c mice (n = 15 each) were vaccinated
three times at 2 weeks intervals; (1) pVAX1-ROP1 (100 µg),
(2) pVAX1 (100 µg), (3) PBS, (4) rROP1 (10 µg), (5) pCold
I, and (6) PBS. Group 1–3 involved intramuscular injection
while group 4–6 were injected subcutaneously. Injection samples
for group 4–6 were mixed evenly with the adjuvants (complete
freund’s, CFA for prime injection; incomplete freund’s, IFA for
booster injections) before immunizing the mice. Mice sera from
each group were collected via tail-bleeding at the end of each
interval. The sera were examined for reaction against extracted
TLA or purified rROP1 via western blot assay. Two weeks after
final injection, three mice from each group were sacrificed by
cervical dislocation and the spleens were collected aseptically for
splenocytes isolation.
In Vitro Lymphocyte Proliferation Assay
Briefly, splenocytes suspensions were prepared from three
immunized mice in each group by pushing the spleens through
a wire mesh. After the red blood cells (RBCs) were removed
using standard Ammonium–Chloride–Potassium (ACK) lysis
buffer, the splenocytes were suspended in RPMI 1640 medium
supplemented with 10% fetal calf serum (FCS), 0.5% gentamicin,
and 1% glutamine. The cells were then plated in 96-well
Costar plates at a density of 2 × 105 cells per well and
cultured with 10 µg/ml TLA or rROP1, 5 µg/ml concanavalin
A (Con A), or with medium alone (negative control) at 37◦C
with 5% CO2. Splenocytes proliferation was measured using
bromodeoxyuridine (BrdU) colorimetric assay according to the
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manufacturer’s instructions (Roche, Indianapolis, IN, USA).
Stimulation index (SI) was calculated as follow.
Stimulation index (SI) = mean OD570 values of stimulated cells
mean OD570 values of unstimulated cells
All assays were performed in triplicate.
Cytokine Assays
Supernatants were harvested from the splenocytes cultures 72 h
after stimulation with TLA or rROP1, ConA, or medium alone.
Cytokines were measured using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (BD Biosciences, San Jose,
CA, USA). The concentration of interleukin-4 (IL-4) and gamma
interferon (IFN-γ) in supernatants were determined using
standard reference curves constructed with known amounts
of recombinant mouse IFN-γ and IL-4. Sensitivities of the
assays are <5 pg/ml and <10 pg/ml for IL-4 and IFN-γ
respectively.
Challenge with T. gondii
The remaining 12 immunized mice from each group were
challenged with 1 × 103 live tachyzoites by intraperitoneal
injections 2 weeks after final injection. The challenged mice were
being monitored over a period of 28 days and their survival
rates were calculated. After 28 days all the surviving mice were
humanely killed by CO2 asphyxiation.
Statistical Analysis
Statistical significance of the data obtained was tested using
Students t-test or ANOVA with SPSS software. P values of <0.05
were considered significant. The graph for the survival curve
was drawn based on the Kaplan–Meier approach (Kaplan and
Meier, 1958). Survival rates were statistically compared using the
chi-square (χ2) test.
RESULTS
Construction of Recombinant Plasmids
Full length open reading frame of ROP1 gene was successfully
amplified from T. gondii genomic DNA producing an amplified
product of 1191 bp (data not shown). The PCR fragment
was cloned into eukaryotic expression vector (pVAX1 and
pVAX1-GFP) and prokaryotic expression vector (pCold I) before
transforming into TOP10F’ and BL21 (DE3) bacterial cells,
respectively. The nucleotide sequence of the recombinant clones
(pVAX1-ROP1, pVAX1-GFP-ROP, and pCold I-ROP1) obtained
were analyzed with BLAST alignment tool which revealed that
they shared 100% similarity of the published coding sequence of
ROP1 (data not shown).
Eukaryotic Expression of
pVAX1-GFP-ROP1 in CHO Cells
ROP1 gene was expressed in CHO cells before performing DNA
immunization study in order to prove that the constructed
pVAX1-ROP1 could be expressed constitutively and that the
expression would not affect the viability of the cells. Transfection
of pVAX1-ROP1 into CHO cell was carried out using
Lipofectamine, a positively charged liposome that interacted with
the negatively charged pVAX1-ROP1 which then facilitated its
entry into the cell by overcoming the electrostatic repulsion.
Entry of the transfection complex into CHO cell occurred
through endocytosis, a process of DNA uptake by the cell
FIGURE 1 | (A–C) Expression of recombinant pVAX-1-GFP-ROP1 plasmid in CHO cells at 72 h post-transfection with: (A) pVAX1-GFP as positive control, (B)
pVAX1-GFP-ROP1, and (C) PBS as negative control. Protein expression was observed under fluorescence microscopy.
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FIGURE 2 | (A,B) Immunoblot analysis on the identity and antigenicity of recombinant ROP1 (rROP1) protein expressed in CHO cells. (A) Western blot probed with
monoclonal anti-GFP antibody. Lanes 2–3 contained cell lysates of pVAX1-GFP-transfected CHO cells. Lanes 4–5 contained cell lysates of
pVAX1-GFP-ROP1-transfected CHO cells. Lanes 6–7 contained cell lysates of mock transfection. (B) Western blot probed with toxoplasmosis-positive patient
serum. Lanes 2–3 contained cell lysates of pVAX1-GFP-transfected CHO cells. Lanes 4–5 contained cell lysates of pVAX1-GFP-ROP1-transfected CHO cells. Lanes
6–7 contained cell lysates of mock transfection. Bound antibodies were detected using alkaline phosphatase-conjugated goat anti-mouse IgG (A) and anti-human
IgG (B), respectively. Lane 1 (A,B) contained protein molecular weight markers. The 68 kDa rROP1 protein was detected (arrow).
FIGURE 3 | (A,B) SDS-PAGE analysis on purified rROP1 protein. (A) Coomassie blue stained. Lanes 2–4 contained purified fractions of purified rROP1 protein.
Lanes 5–7 contained purified fractions of negative control. (B) Western blot probed with monoclonal anti-His antibody. Lanes 2–4 contained purified fractions of
purified rROP1 protein. Lanes 5–7 contained purified fractions of negative control. Lane 1 (A,B) contained protein molecular weight markers. The 43 kDa purified
rROP1 was detected (arrow).
membrane followed by diffusion through cytoplasm to reach the
cell nucleus.
Expression of GFP-tagged ROP1 protein was observed
fluorescing in green under inverted fluorescence microscopy
compared to the negative control (Figure 1). Expression of
GFP protein in the pVAX1-GFP-transfected CHO cells served as
positive control. GFP acts as a biosensor that helps to identify
protein expression in mammalian cells which will exhibits green
fluorescence when exposed to light in the ultraviolet region. The
identity of the expressed rROP1 protein was further confirmed
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FIGURE 4 | (A,B) Immunoblot analysis of antibody production in the vaccinated mice. (A) Detection of specific anti-TLA antibody in DNA vaccinated mice sera.
Lanes 2–3 contained pVAX1-ROP1-immunized mice sera. Lanes 4–5 contained pVAX1-injected mice sera. Lanes 6–7 contained PBS-injected mice sera.
Representative results from two of the 12 mice tested are presented. (B) Detection of specific anti-ROP1 antibody in protein vaccinated mice sera. Lanes 2–6
contained rROP1-immunized mice sera. Lanes 7–11 contained vector protein-injected mice sera. Lanes 12–16 contained PBS-injected mice sera. Lane 1 (A,B)
contained protein molecular weight markers. The 43 kDa ROP1 antigen was detected (arrow).
TABLE 1 | Characterization of cellular-mediated immunity in
DNA-vaccinated mice.
Group (n = 3) Proliferation (SI) Cytokine level (pg/ml)
IFN-γ IL-4
pVAX1-ROP1 2.04 ± 0.12∗∗∗ 712 ± 28.1∗∗∗ 94 ± 14.5∗∗
pVAX1 0.6 ± 0.09 48 ± 10.8 50 ± 13.6
PBS 0.4 ± 0.04 45 ± 6.6 47 ± 6.1
SI stands for stimulation index.
Data are expressed as mean ± SD (n = 3). Statistical difference are represented by
∗∗∗p < 0.001, in comparison with the control groups (PBS or pVAX1). ∗∗ represents
p < 0.01.
by western blotting against monoclonal anti-GFP antibody and
toxoplasmosis-positive human serum. A protein band at the size
of approximately 68 kDa was detected corresponding to the
predicted size of GFP-tagged rROP1 protein (Figure 2). The
protein size is about 27 kDa greater than that of the native
ROP1 due to the fusion of the 24 kDa GFP protein to the
rROP1 protein as well as the post-translational modification
factor. Similarly, ROP1 was successfully expressed in mammalian
expression vector pCMV-Tag2B with the native size of 43 kDa
and was found to be immunogenic in vivo and in vitro (Quan
et al., 2012).
Prokaryotic Expression and Purification
of rROP1
SDS-PAGE analysis showed that rROP1 was successfully
expressed and purified with target size of approximately 43 kDa as
depicted in Figure 3A with the purified vector protein as negative
control. Meanwhile, monoclonal anti-His antibody detected a
band with the similar size as shown in Figure 3B, thereby
confirming the identity of rROP1 fused with the His-tag.
The pCold I vector used to clone the target ROP1 gene
contained cspA gene encoding for cold-shock protein which
is responsible for protein expression at low temperature
thereby preventing production of insoluble protein. Soluble
rROP1 of approximate protein size of 43 kDa containing the
polyhistidine tag (Hengen, 1995) was expressed with optimal
IPTG concentration of 1 mM and was purified based on affinity
chromatography under native condition. The purification resins
involved Ni2+ ions that bind to the histidine tag within rROP1
followed by elution of the bound rROP1 by imidazole salts.
Humoral Immune Response Elicited by
the Immunized Mice
pVAX1-ROP1
Sera collected from pVAX1-ROP1 vaccinated mice were shown to
react with TLA, detecting a protein size of approximately 43 kDa
(Figure 4A) which corresponded to the estimated molecular
weight of native ROP1. Meanwhile, no specific anti-Toxoplasma
IgG antibody was detected in sera from both negative control
groups (pVAX1 or PBS).
rROP1
Sera collected from rROP1 vaccinated mice were shown to react
with purified rROP1, detecting a protein size of approximately
43 kDa (Figure 4B) which corresponded to the estimated
molecular weight of native ROP1. Meanwhile, no specific anti-
ROP1 IgG antibody was detected in sera from both negative
control groups (pCold I or PBS).
Lymphoproliferative Response of the
Immunized Mice
pVAX1-ROP1
Single cell suspension of the splenocytes was prepared 2 weeks
after final immunization in order to evaluate the proliferative
Frontiers in Microbiology | www.frontiersin.org 6 May 2016 | Volume 7 | Article 808
fmicb-07-00808 May 25, 2016 Time: 16:29 # 7
Sonaimuthu et al. Protective Immunity of Rhoptry-1
FIGURE 5 | (A,B) Cell proliferation assay. In vitro splenocytes proliferation assay of mice immunized with (A) pVAX1-ROP1 and (B) rROP1. The proliferation results
(stimulation index) are expressed as mean ± SD (n = 3). Statistical difference are represented by ∗∗∗p < 0.001, in comparison with the respective negative controls.
TABLE 2 | Characterization of cellular-mediated immunity in
protein-vaccinated mice.
Group (n = 3) Proliferation (SI) Cytokine level (pg/ml)
IFN-γ IL-4
rROP1 3.04 ± 0.21∗∗∗ 1457 ± 31.19∗∗∗ 186 ± 14.17∗∗
pCold 1 0.62 ± 0.16 102 ± 13.50 86 ± 9.29
PBS 0.57 ± 0.04 96 ± 10.21 75 ± 6.11
SI stands for stimulation index.
Data are expressed as mean ± SD (n = 3). Statistical difference are represented
by ∗∗∗p < 0.001, in comparison with the control groups (PBS or pCold 1).
∗∗ represents p < 0.01.
immune response induced. Stimulated spleen cells of the
vaccinated mice showed a significant proliferative response to
TLA as compared to the non-vaccinated mice (p < 0.001) with
SI value of 2.04± 0.12 (pVAX1-ROP1), 0.6± 0.09 (pVAX1), and
0.4± 0.04 (PBS; Table 1 and Figure 5A).
rROP1
Results obtained indicated that the SI value for stimulated
splenocytes isolated from mice immunized with rROP1
(3.04 ± 0.21) was significantly higher than that of the mice
immunized with vector protein (0.62 ± 0.16) and PBS
(0.57± 0.04; p< 0.001) as shown in Table 2 and Figure 5B.
Cytokines Levels Produced by the
Immunized Mice
pVAX1-ROP1
Stimulated splenocytes culture supernatants of the immunized
mice were harvested 72 h post-induction with TLA to evaluate
IFN-γ and IL-4 production level through ELISA. Significantly
higher level of IFN-γ (712 ± 28.1 pg/ml) was secreted by
the pVAX1-ROP1 immunized mice splenocytes compared to
that of pVAX1 (48 ± 10.8 pg/ml) and PBS (45 ± 6.6 pg/ml;
p < 0.001). On the other hand, higher level of IL-4 was also
detected in the splenocytes supernatants from the vaccinated
mice (94 ± 14.5 pg/ml) as compared to the negative control
groups; 50± 13.6 pg/ml and 47± 6.1 pg/ml for pVAX1 and PBS,
respectively (p< 0.01; Table 1 and Figure 6A).
rROP1
Stimulated splenocytes culture supernatants of the immunized
mice were harvested 72 h post-induction with purified rROP1
to evaluate IFN-γ and IL-4 production level through ELISA.
Significantly higher level of IFN-γ (1457 ± 31.19 pg/ml) was
secreted by the rROP1 immunized mice splenocytes compared to
that of pCold I (102 ± 13.50 pg/ml) and PBS (96 ± 10.21 pg/ml;
p < 0.001). On the other hand, higher level of IL-4 was detected
in the supernatant of splenocytes from the vaccinated mice
(186± 14.17 pg/ml) as compared to the negative control groups;
86 ± 9.29 pg/ml and 75 ± 6.11 pg/ml for pCold I and PBS,
respectively (p< 0.01; Table 2 and Figure 6B).
Protective Immunity against T. gondii
Challenge
pVAX1-ROP1
Parasites challenging study revealed that mice immunized with
pVAX1 and PBS had a mean survival time of 5 days and all died
within the first 9 days. In contrast, mice immunized with pVAX1-
ROP1 survived up to 16 days with mean survival time of 23 days
(p< 0.05). Within the first 9 days, the vaccinated mice had 100%
survival rate compared to control mice which all had succumbed
to T. gondii infection (Figure 7A).
rROP1
Results indicated that rROP1-immunized mice significantly
prolong their survival days (20 days; mean survival of 29 days)
in comparison to pCold I- and PBS-injected mice (14 days; mean
survival of 7.5 days; p < 0.05). Within the first 14 days, the
vaccinated mice had 100% survival rate compared to control mice
which had 100% mortality (Figure 7B).
DISCUSSION
In our study, mice vaccinated with pVAX1-ROP1 and rROP1
survived longer than the controls when challenged with lethal
Frontiers in Microbiology | www.frontiersin.org 7 May 2016 | Volume 7 | Article 808
fmicb-07-00808 May 25, 2016 Time: 16:29 # 8
Sonaimuthu et al. Protective Immunity of Rhoptry-1
FIGURE 6 | (A,B) Cytokine assay. Cytokine production from the stimulated splenocyte culture supernatants of mice immunized with (A) pVAX1-ROP1 and (B)
rROP1. Data are expressed as mean ± SD (n = 3). Statistical difference are represented by ∗∗p < 0.01 or ∗∗∗p < 0.001, in comparison with the respective negative
controls.
FIGURE 7 | (A,B) Study of protective immunity against T. gondii infection. Survival rate of mice immunized with (A) pVAX1-ROP1 and (B) rROP1 after lethal
challenge with 1 × 103 tachyzoites compared to the respective negative controls. Each group consisted of 12 mice.
dose of virulent T. gondii RH strain. This protection is
likely through humoral and cell-mediated immune responses
with secretion of high IFN-γ level but low IL-4 level. An
increase in the IFN-γ along with low levels of IL-4 is
prerequisite for a Th1-dependent protective immune response
(Yan et al., 2012; Parthasarathy et al., 2013). There was
a significant correlation between IFN-γ level and degree
of protection conferred, suggesting IFN-γ-dependent Th1-
predominant immunity is critical for protection against T. gondii
infection (Ismael et al., 2003; Yuan et al., 2011a). These
findings are corresponded to previous reports describing the
induction of protective Th1-cell mediated immunity against
T. gondii infection (Gazzinelli et al., 1991; Denkers and
Gazzinelli, 1998; Jordan and Hunter, 2010; Yuan et al., 2011a,b).
Survival of the vaccinated mice is mainly dependent on the
cellular immunity mediated by both CD4+ and CD8+ cells
through cytokine secretion especially interferon-gamma (IFN-γ).
IFN-γ plays a major role in protecting the infected hosts against
T. gondii infection (Suzuki and Remington, 1990; Gazzinelli
et al., 1991). It helps to activate phagocytes such as macrophages
to limit the multiplication and spreading of the parasites
(Filisetti and Candolfi, 2004). The up-regulation of CD8+ T
lymphocytes activity in the IFN-γ-treated mice showed that this
cytokine is essential for evoking CD8+ T cell responses during
parasitic infection (Ely et al., 1999). Meanwhile, interleukin-
4 (IL-4) that was produced in relatively low level in our
study is secreted by CD4+ Th2 cells. IL-4 involves in the
activation and differentiation of both T and B lymphocytes
besides enhancing the MHC-II antigens expression (Filisetti and
Candolfi, 2004).
The potential of ROP1 as DNA vaccine candidate has been
reported in previous studies (Chen et al., 2001, 2003; Guo
et al., 2001; Li et al., 2010; Hiszczynska-Sawicka et al., 2011a;
Eslamirad et al., 2012; Quan et al., 2012). Partial ROP1 sequence
(765 bp) was cloned into pcDNA vector to construct recombinant
DNA for vaccination in mice, in which high IFN-γ level was
produced together with increased proliferation of splenocytes
(Chen et al., 2001; Guo et al., 2001). It was also reported that DNA
vaccine encoding the truncated ROP1 fragment incorporated
with SAG1 that was cloned in pEGFP-N3 vector successfully
triggered both humoral- and cellular-mediated immune response
in the vaccinated mice (Chen et al., 2003). However, challenge
study involving the vaccinated mice with T. gondii live parasites
were not performed in these studies. Meanwhile, Th1-mediated
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immunity was elicited by recombinant pcDNA-ROP1 (ROP1
partial sequence) DNA plasmid-immunized BALB/c mice with
elevated IFN-γ level but low IL-4 production. However, it fails
to protect the vaccinated mice against lethal dose (105) of
virulent RH strain of T. gondii (Eslamirad et al., 2012). In
contrast to our study, we had generated pVAX1-ROP1 using
full length ROP1 sequence and involved lower dose (103) of
the similar parasitic strain. Similarly to our study, full length
ROP1 sequence was employed and cloned in different vector
(pCMV-Tag2B) before immunizing experimental mice model
which induced same type of immunity. Nevertheless, different
T. gondii strain which is less virulent (ME49) was used to
challenge the immunized mice (Quan et al., 2012). In addition,
several other rhoptry genes have also been evaluated in DNA
vaccination studies such as ROP8, ROP16, and ROP18 delivered
via pVAX1 eukaryotic expression vector with slightly higher
survival times reported (Yuan et al., 2011a,b; Parthasarathy et al.,
2013).
On the other hand, protective efficacy of the subunit
vaccines of Toxoplasma recombinant antigens produced
in bacterial cells was evaluated against T. gondii infection
in the experimental mice as well which was able to
demonstrate certain degree of immunoprotections (Mishima
et al., 2001; Martin et al., 2004; Yang et al., 2004; Dziadek
et al., 2012; Ching et al., 2016). Various combinations of
subunit vaccines using rROP2, rROP4, rGRA4, and rSAG1
have been tested, and it was the rROP2+rROP4+rSAG1
combination conferred the strongest protection against chronic
toxoplasmosis in mice (Dziadek et al., 2012). Another study
reported generation of mix mode Th1/Th2-immune responses
primarily Th1 in the rGRA2 and rGRA5-vaccinated mice
with prolonged survival rates against acute toxoplasmosis
(Ching et al., 2016). Nevertheless, this study is the first report
depicting the immunogenicity and protectivity of rROP1
subunit vaccine against acute toxoplasmosis in the mouse
model.
CONCLUSION
Our study found strong and specific immunity induced by the
ROP1 based vaccine (DNA plasmid and protein), and partial
protection was obtained in vaccinated BALB/c mice. Therefore,
ROP1 should be considered as a potential vaccine candidate
for toxoplasmosis. Complete protection may be achieved by
combining ROP1 with other immunogenic rhoptry antigens.
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